Satellite Symposium:
Hot Topics in HIV Management: You Pick the Case (Not Official IDWeek Programming - This activity is supported by an educational grant from ViiV Healthcare. - See Affiliated Events Guide)
Thursday, October 27, 2016: 5:30 PM-8:00 PM
Room: 278-282

Learning Objectives:

All Satellite Symposia, Presentation Theaters, and Learning Lounges preceding and following the official program IDWeek 2016 are independently organized and executed.  IDWeek does not endorse or support the programming of any Symposia, Presentation Theater, or Learning Lounge.


Faculty:

Paul E. Sax, MD

Clinical Director, Division of Infectious Diseases

Brigham and Women's Hospital

Professor of Medicine

Harvard Medical School

Boston, MA

 

Eric S. Daar, MD

Chief, Division of HIV Medicine

Harbor-UCLA Medical Center

Professor of Medicine

David Geffen School of Medicine at UCLA

Torrance, CA

 

Richard A. Elion, MD

Associate Clinical Professor of Medicine

George Washington University School of Medicine

Co-Director, DC Dept of Health STD Research Program

Washington, DC

 

Joseph J. Eron, Jr., MD

Professor of Medicine, Division of Infectious Diseases

University of North Carolina at Chapel Hill School of Medicine

Chapel Hill, NC

 

Program Objectives:

Upon successful completion of this educational activity, participants should be

better able to:

  • Apply evidence-based guidelines and knowledge of the clinical safety, efficacy, and recommended usage of available and emerging therapies to select initial HIV therapy based on individual patient characteristics.

  • Utilize simplified regimens that reflect patient preference as a means to increase adherence when selecting HIV therapy.

  • Compare and contrast the resistance profiles of available and emerging HIV treatment regimens.

  • Evaluate the effective use of switch strategies and NRTI-sparing regimens that have demonstrated a low risk of virological failure in patients who would benefit from treatment alteration. 

     

    Accreditation Statement:

    National Jewish Health designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

     

    This program is acceptable for 2.0 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-9999-16-008-L01-P, effective 10/27/2016. This is an application-based activity and there is no fee to attend.

     

    To receive credit, physicians and pharmacists must attend the entire presentation and complete the evaluation at the end of the program. Credit Claim Forms will be available onsite. 

     

    Agenda subject to change and was provided by:

    Vindico Medical Education; 6900 Grove Road, Thorofare, NJ 08086; P. 856-994-9400; F. 856-384-6680; E.cme@vindicocme.com.

     

Please contact Kristin Riday directly at 856-994-9400 ext. 463 or kriday@vindicocme.com  for more information.

Target Audience: Infectious diseases physicians

Presentations:
5:30 PM
Introduction and Pretest Paul E. Sax, MD
6:00 PM
Registration and Dinner
6:10 PM
Advances in HIV Therapy: Simplifying Options for Patients Paul E. Sax, MD
6:30 PM
Case Choice: Selecting an Initial ART Regimen Richard A. Elion, MD
6:45 PM
Question and Answer
6:50 PM
Case Choice: Switching ART in Virologically Suppressed Patients Joseph J. Eron, Jr., MD
7:05 PM
Question and Answer
7:10 PM
Case Choice: Managing Treatment-experienced HIV Patients with Virologic Failure Eric S. Daar, MD
7:25 PM
Question and Answer
7:30 PM
Panel Discussion Moderated by Paul E. Sax, MD
7:45 PM
Posttest and Question and Answer

CME Credits: No CME credit is offered for this session.

ACPE Credits:

ACPE Number:


See more of: Satellite Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.